With the rise of illness and its effect on the global population, innovation and research are among the new approaches enforced by biotechnology companies today. Among those in the forefront in the fight against cancer is a Seattle-based biotech company, Seattle Genetics. Led by faithful President and CEO Clay Siegall, the company continues to prosper making strides in pharmaceutical advancements to eradicate terminal disease.
With a Ph.D. in Genetics, Clay Siegall had his start in the pharmaceutical industry from as early as 1988 where he worked in the National Institutes of Health. Up to ten years later, he co-founded Seattle Genetics in 1998 that specializes in antibody drug coagulates (ADC). The drug’s sole purpose once administered to cancer patients is to target cancerous cells killing them effectively. The drugs provide the lifesaving benefits of cancer therapy without the deadly effects of chemotherapy. A passion for saving lives propels the organization and their research to ensure the medication manufactured makes life easier for cancer patients. In the course of his career, Clay Siegall has had 15 patents, in addition to 70 publications drawing from his experience and extensive research in the pharmaceutical sector in the hopes of bettering the lives of the ailing.
With Siegall at the helm as CEO, he continues to apply industry knowledge to steer Seattle Genetics to success. Apart from being publicly traded on NASDAQ and SGEN, the corporation has seen success outside of the United States of America. Distributed in at least 11 countries, Seattle Genetics continues to produce drugs to remedy the many patients that suffer from the debilitating effects of cancer. Collaborating with large pharmaceutical companies, he raised capital to create financing for the researching, testing, and production of drugs. Among some of the most profitable licensing partnerships were formed with pharmaceutical giants Pfizer and GlaxoSmithKline. Though the fight continues to a cancer-free world, Seattle Genetics continues to learn from their clinical trials to develop better drugs. As the organization makes progress in providing a cure to cancer, Seattle Genetics’ 650 employees lead by its passionate leader Seigall work tirelessly to eradicate cancer in the near future.